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Abstract 
KRAS activation and PTEN inactivation are frequent events in endometrial tumorigenesis, 
occurring in 10-30% and 26-80% of endometrial cancers, respectively. As we have recently 
demonstrated activating mutations in fibroblast growth factor receptor 2 (FGFR2) in 16% of 
endometrioid endometrial cancers, we sought to determine the genetic context in which FGFR2 
mutations occur. Analysis of 116 primary endometrioid endometrial cancers revealed FGFR2 and 
KRAS mutations were mutually exclusive, whereas FGFR2 mutations were seen concomitantly 
with PTEN mutations. Here we show that shRNA knockdown of FGFR2 or treatment with a pan-
FGFR inhibitor, PD173074, resulted in cell cycle arrest and induction of cell death in endometrial 
cancer cells with activating mutations in FGFR2. This cell death in response to FGFR2 inhibition 
occurred within the context of loss-of-function mutations in PTEN and constitutive AKT 
phosphorylation, and was associated with a marked reduction in ERK1/2 activation.  Together these 
data suggest inhibition of FGFR2 may be a viable therapeutic option in endometrial tumors 
possessing activating mutations in FGFR2, despite the frequent abrogation of PTEN in this cancer 
type.   
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Introduction 
Endometrial cancer is the most commonly diagnosed malignancy of the female reproductive 
tract in the United States.  It was estimated that 39,080 new cases of cancer of the uterine corpus 
would be diagnosed and 7,400 women would die of this disease in the United States in 2007 (1). 
The majority of women presenting with endometrial cancer are surgically cured with a 
hysterectomy; however, about 15% of women demonstrate persistent or recurrent tumors that are 
refractory to current chemotherapies. For those women with advanced stage, progressive, or 
recurrent disease, survival is poor as there are no adjuvant therapies proven to be effective. The 
five-year survival for patients who have recurred is only 13% (2). 
A variety of somatic gene defects have been reported in endometrial carcinoma. Well or 
moderately differentiated endometrioid endometrial carcinomas account for approximately 80% of 
uterine cancers and are characterized by a high frequency of inactivating mutations in PTEN (26-
80%), activating KRAS mutations (10-30%), and gain-of-function CTNNB1 (β-catenin) mutations 
(25-38%) (3).  Our laboratory recently reported mutations in fibroblast growth factor receptor 2 
(FGFR2) in 19/187 (10%) primary uterine tumor samples (4).  Mutations were seen primarily in 
tumors of the endometrioid histologic subtype (18/115, 16%). The majority of the somatic 
mutations identified were identical to germline activating mutations in FGFR2 and FGFR3 that 
cause a variety of craniosynostosis and skeletal dysplasia syndromes (4).  
The discovery of activating FGFR2 mutations in endometrial carcinoma raises the 
possibility of employing anti-FGFR molecularly targeted therapies in patients with advanced or 
recurrent endometrial carcinoma.   Indeed, recent studies have indicated FGFRs hold promise as 
targets for anti-cancer therapy. The efficacy of FGFR inhibitors to inhibit cancer cell growth in vitro 
and in vivo has been investigated in a variety of malignancies, including myeloma  (5) and bladder 
cancer (6), with significant inhibition of cell growth observed following FGFR inhibition.   
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Here we present evidence that activating mutations in FGFR2 occur within the context of 
PTEN inactivation, but are mutually exclusive with KRAS mutations in endometrioid endometrial 
tumors.  Using endometrial cancer cell lines expressing mutationally activated FGFR2 and wildtype 
or mutant PTEN, we demonstrate inhibition of activated FGFR2, either through shRNA knockdown 
or treatment with a pan-FGFR inhibitor, PD173074, results in cell death, even within the context of 
PTEN inactivation. Together these data suggest that FGFR2 may be a viable therapeutic target in 
endometrial cancer, despite the high frequency of PTEN abrogation in this tumor type. 
 
Materials and Methods 
 
Study Subjects and Clinical Data.  Tumor and matched normal tissue samples were collected 
from hysterectomy specimens from patients being treated for suspected uterine cancer over the 
period 1993-2005.  All participants consented to molecular analyses and follow-up as part of a 
Washington University Medical Center Human Studies Committee approved protocols (HSC 93-
0828).  Tissue specimens collected for research were evaluated and diagnoses confirmed by 
experienced gynecologic pathologists. Given our previous observation that FGFR2 mutations are 
largely restricted to the endometrioid subtype of endometrial cancer (4), our studies were limited to 
this histologic subtype.  The 116 patient specimens analyzed were originally selected to over-
represent cases with tumor MSI and those patients with advanced stage disease (Supplemental 
Table 1), in order to assess whether FGFR2 mutations were more common in MSI positive tumors 
and whether FGFR2 mutations were restricted to early stage cancer, as has been reported for 
FGFR3 mutations in bladder cancer (4).  Clinical data were extracted from clinic charts, hospital 
records and Barnes-Jewish Hospital Oncology Data Services.  
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MSI Typing. Tissue specimens and blood were obtained at the time of surgery, snap frozen and 
stored at -70 ºC.   DNA was prepared from neoplastic cellularity (>70%) using proteinase K and 
phenol extraction or with the DNeasy Tissue Kit (Qiagen Inc, Valencia, CA). Matched normal DNA 
was extracted from peripheral blood leukocytes as previously described (7).  Microsatellite analysis 
was performed as previously described (7) using five National Cancer Institute consensus 
microsatellite markers (BAT25, BAT26, D2S123, D5S346 and D17S250). Tumors were classified as 
MSI+ if novel PCR bands were identified in at least two of the five consensus panel markers.  
Tumors were considered microsatellite stable (MSI-) if there was no evidence of MSI in any 
marker. 
 
Sequencing Analysis. Mutation analysis was performed as previously described (4). PCR primer 
sequences, listed in Supplemental Table 2, were M13 tailed and sequencing performed in two 
directions.  
 
Cell Culture and Reagents.  The MFE296 cell line was purchased from the European Collection 
of Cell Cultures (Salisbury, Wiltshire, UK). AN3CA, HEC1A, Ishikawa, RL952, and KLE were 
provided by Dr. Paul Goodfellow (Washington University, St. Louis, MO). PD173074 was 
purchased from Sigma-Aldrich (St. Louis, MO). The KH1-LV lentivector plasmid was kindly 
provided by Dr. Maria S. Soengas (University of Michigan, Ann Arbor, MI), and lentiviral 
packaging plasmids were kindly provided by Dr. Matthew Huentelman (Translational Genomics 
Research Institute, Phoenix, AZ). 
 
Lentiviral Transduction of shRNA.  Two independent shRNA constructs, targeting two different 
exons of FGFR2 (exon 2 and exon 15), were designed against the following sequences:  shRNA 
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targeting exon 2: 5’-TTAGTTGAGGATACCACATTA-3’ (nucleotides 79-99, NM_022970); 
shRNA targeting exon 15: 5’-ATGTATTCATCGAGATTTA-3’ (nucleotides 1866-1884, 
NM_022970). A nonsilencing shRNA construct was also designed based on a nonsilencing siRNA 
sequence from Qiagen (5’-AATTCTCCGAACGTGTCACGT-3’), and was used as a negative 
control. The corresponding oligonucleotides were annealed and cloned into a self-inactivating 
lentiviral vector (8).  Virus production and cell transduction was performed as described (9). Greater 
than 90% transduction efficiency was achieved in each shRNA experiment, as determined by eGFP 
visualization (data not shown). 
 
Growth Inhibition Assay.  Twenty-four hours after infection, cells were plated in 96 well plates at 
a density of 5,000 cells per well and proliferation assessed on multiple days using the 
Sulforhodamine B (SRB) assay (Sigma-Aldrich, St. Louis, MO). 
  
FACS analysis. Cells were transfected with 25nM nonsilencing (NS) siRNA or FGFR2 siRNA X2 
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA).  48 hours after transfection, floating and 
attached cells were collected and analyzed for annexin staining according to the manufacturer’s 
instructions (BioVision, Inc. Mountain View, CA) using a CyAn ADP flow cytometer and Summit 
software, version 4.3 (Dako Cytomation, Carpinteria, CA).  For PD173074 studies, cells were 
treated with 1µM PD173074 and annexin staining evaluated at the indicated time points. For 
UO126 studies, cells were treated with 25 µM UO126 (Sigma-Aldrich, St. Louis, MO) and annexin 
staining evaluated 72 hours after treatment. For cell cycle analysis, cells were treated with 1µM 
PD173074 and 72 hours later were stained with propidium iodide as described (10). Cell cycle 
analysis was performed using ModFit software (Verity Software House, Inc. Topsham, ME).   
 
 7
Immunoprecipitation and Western Blot Analysis 
For PD173074 studies, cells were starved overnight in 0.2% FBS and then incubated with 1µM 
PD173074 for 0 to 72 hours. For shRNA studies, 24 hours after lentiviral transduction, cells were 
starved overnight in 0.2% FBS and then lysates collected. For p-FGFR2 and p-FRS2α studies, 
AN3CA cells were starved overnight in 0.2% FBS, pretreated with 1µM PD173074 for 1 hour, and 
then stimulated with 1nM FGF7 and 10µg/ml heparin for 5 minutes.  500µg of AN3CA lysate was 
immunoprecipitated with 2 µg of a FGFR2 specific antibody (Bek C-17; Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA), and western blot analysis was performed using a phospho-specific FGFR 
antibody (pFGFR Tyr653/654; Cell Signaling Technology, Beverly, MA).  The western blot was 
then stripped and reprobed for total FGFR2 (Bek C-17).  pFGFR (Tyr653/654), pFRS2α  (Tyr197), 
AKT and ERK1/2 antibodies were purchased from Cell Signaling Technology (Beverly, MA) and 
total FGFR2 (BekC17) and FRS2α  antibodies were from Santa Cruz Biotechnology, Inc. (Santa 
Cruz, CA).  
 
Statistical Analysis 
Statistical analyses were performed using GraphPad Prism version 4.0 for Macintosh (GraphPad 
Software, San Diego, CA). IC50 values were calculated by dose-response analysis using nonlinear 
regression of sigmoidal dose response with variable slope. All p values were considered significant 
when p<0.05.  Data were expressed as mean ± SE. 
  
Results 
Patterns of FGFR2, PTEN and KRAS mutations in primary endometrial cancers. Given that 
PTEN and KRAS mutations are common in endometrioid endometrial cancer, and as FGFRs signal 
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through the MAPK and PI3K pathways, we first sought to determine whether FGFR2 mutations 
occurred in tumors that harbor gain-of-function mutations in KRAS and/or loss-of-function 
mutations in PTEN. We sequenced all nine exons of PTEN and exon one of KRAS in 116 
endometrioid endometrial tumors for which we knew the FGFR2 mutation status. Due to the 
limiting amount of DNA available, we only sequenced exon one of KRAS, as mutations in exon one 
account for greater than 96% of KRAS mutations in endometrioid endometrial cancer4. KRAS 
mutations were identified in 12% (15/116) of tumors (Supplemental Table 1). Activating mutations 
in FGFR2 and KRAS were mutually exclusive (Table 1).  Of note, one tumor possessed a frameshift 
mutation in FGFR2 (2290-91 del CT) and contained a KRAS mutation.  However, as the pathogenic 
nature of this FGFR2 mutation is unknown, we concluded that activating mutations in FGFR2 were 
mutually exclusive with activating mutations in KRAS.  Mutation analysis revealed PTEN 
mutations in 70% (82/116) of tumors (Supplemental Table 1). Of those tumors with FGFR2 
mutations, 77% (14/18) also carried a PTEN mutation (Table 1), demonstrating that mutations in 
FGFR2 frequently occur alongside PTEN mutations in endometrioid endometrial tumors. As 
previously reported (11), PTEN mutations also occur alongside KRAS mutations (Table 1).   
 
shRNA knockdown of FGFR2 induces cell death in endometrial cancer cells, despite PTEN 
inactivation.  Given the occurrence of activating FGFR2 mutations within the context of PTEN 
inactivation in endometrial cancer and the known role of the PI3K/AKT pathway in promoting cell 
survival, we sought to determine whether inhibition of FGFR2 could induce cell death in the 
presence of PTEN inactivation. AN3CA and MFE296 endometrial cancer cells were selected as 
models for these studies.  AN3CA cells reflect the majority (~82%) of primary tumors with 
activating FGFR2 mutations, as these cells carry an activating mutation in the kinase domain of 
FGFR2 (N550K) and exhibit PTEN abrogation.  AN3CA cells have mutations in both PTEN alleles 
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and do not express PTEN (Supplemental Figure 1).  MFE296 cells model the ~18% of primary 
tumors with FGFR2 mutations that were wildtype for PTEN, as these cells express mutationally 
activated FGFR2 (N550K) and are wildtype for PTEN4. 
Knockdown of FGFR2 with two independent shRNAs inhibited cell proliferation in both 
AN3CA and MFE296 cells (Figure 1A, B), demonstrating the effectiveness of targeting activated 
FGFR2 even in the presence of PTEN inactivation. As shown in Figure 1C, shRNA knockdown of 
FGFR2 resulted in greater than 90% reduction in FGFR2 protein in AN3CA cells and a marked 
decrease in ERK1/2 phosphorylation.  No change in AKT phosphorylation was evident (Figure 1C). 
To investigate whether knockdown of FGFR2 induced apoptosis, AN3CA cells were 
transfected with siRNA targeted towards FGFR2 and labeled with annexinV-FITC to detect exposed 
phosphatidylserine by flow cytometry. An increase in annexin-positive staining was evident 
following transfection with FGFR2 siRNA compared to the nonsilencing siRNA control, indicating 
that these cells were undergoing apoptosis (Figure 1D).  
Endometrial cancer cells expressing activated FGFR2 are sensitive to PD173074, a pan-FGFR 
inhibitor.  Six endometrial cancer cell lines (2 mutant N550K FGFR2, and 4 wildtype FGFR2) 
were treated with increasing concentrations of PD173074, a pan-FGFR tyrosine kinase inhibitor.  
PD173074 was highly selective for FGFRs in a screen of 224 kinases, inhibiting FGFR1, FGFR2, 
and FGFR3 at low nanomolar concentrations (12). As shown in Figure 2A, the two endometrial 
cancer cell lines with mutant FGFR2 (AN3CA, MFE296) were 10-40x more sensitive to inhibition 
with PD173074 than cell lines with wildtype FGFR2. The AN3CA line, which has loss-of-function 
mutations on both PTEN alleles, was the most sensitive cell line. Annexin V-FITC labeling 
indicated that ~70% of AN3CA cells were undergoing apoptosis 96 hours after drug treatment 
(Figure 2B).  In addition, cell cycle analysis revealed PD173074 treatment induced G1 arrest of 
AN3CA cells (Figure 2C). 
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Activation status of ERK1/2 and AKT following PD173074 treatment.  We next evaluated 
ERK1/2 and AKT activation at various time points following PD173074 treatment. FGFR inhibition 
resulted in a marked reduction in ERK1/2 activation in AN3CA and MFE296 cells (Figure 3A).  
Phosphorylated ERK1/2 began to return 24-48 hours after PD173074 treatment, but was still below 
baseline activation at 72 hours.  No change in ERK1/2 activation was detectable in HEC1A cells 
(Figure 3A), which are wildtype for FGFR2.  PD173074 treatment resulted in a modest reduction in 
phosphorylated AKT at Threonine 308 and had no effect on phosphorylation at Serine 473 in 
AN3CA and MFE296 cells (Figure 3A). The constitutive activation of AKT in the AN3CA cell line 
in 0.2% FBS is likely due to inactivation of both PTEN alleles; the mechanism of constitutive AKT 
activation is unknown in MFE296 cells as they express wildtype PTEN and PIK3CA4. No change in 
phosphorylation of Serine 473 was detected in HEC1A cells.  As previously reported (13), HEC1A 
cells showed minimal activation of pAKT at Threonine 308 (Figure 3A).      
 To confirm that the observed effects are due to FGFR2 inhibition, AN3CA cells were 
pretreated for 1 hour with 1 µM PD173074, stimulated with 1 nM FGF7 for five minutes, and 
phosphorylation of FGFR2 and FRS2α, an adaptor molecule downstream of FGFRs (14), assessed. 
As shown in Figure 3B, PD173074 pretreatment efficiently blocked both basal and FGF7-
stimulated phosphorylation of FGFR2 and FRS2α.  
 
DISCUSSION 
Understanding the molecular basis of tumor progression has led to the development and 
success of targeted therapies in a variety of cancer types.  There is increasing evidence that 
activating mutations in genes involved in various signaling pathways can result in “addiction” of 
tumor cells to these pathways (15).  Furthermore, these activating mutations serve not only to 
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identify potential therapeutic targets but their presence can also predict clinical response to pathway 
inhibition (16).  However, it has become increasingly clear that the response to target inhibition is 
also influenced by the molecular context wherein these mutations occur.  As we have previously 
identified activating mutations in FGFR2 in ~16% of endometrioid endometrial tumors (4), here we 
sought to investigate the genetic context in which FGFR2 mutations occur in endometrial cancer.  
We also sought to evaluate the therapeutic potential of targeting activated FGFR2 by investigating 
the biological consequence of inhibiting FGFR2 in endometrial cancer cells possessing activating 
mutations in FGFR2. 
In the present study, we evaluated the KRAS and PTEN mutation status of endometrioid 
endometrial tumors with known FGFR2 mutation status.  Activating KRAS and FGFR2 mutations 
did not occur together in the same tumor, consistent with FGFR2 driving tumorigenesis through the 
MAPK pathway. FGFR2 activation occurred alongside PTEN inactivation, suggesting that, at least 
in endometrial cells, FGFR2 does not mediate its biological effect through PI3K/AKT. This is 
supported by one previous report where FGF7 or FGF10 stimulation of endometrial cells resulted in 
ERK1/2, but not AKT, activation (17).  The role of MAPK in FGFR2-mediated effects is further 
supported by our signaling studies, where inhibition of FGFRs resulted in a rapid and robust 
decrease in ERK1/2 activation but had a very modest effect on AKT phosphorylation (Figures 1 and 
3).  
We have also shown that FGFR2 signaling is essential for survival and proliferation of 
endometrial cancer cell lines with activating FGFR2 mutations.  This is supported by the IC50 
studies in which we demonstrated the two cell lines with mutationally activated FGFR2 were 
selectively sensitive to the pan-FGFR inhibitor, PD173074.  It is noteworthy that the AN3CA cells, 
which demonstrate abrogation of PTEN, were the most sensitive to PD173074. This is of particular 
importance given the high incidence of PTEN mutation in endometrioid endometrial cancer and the 
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suggestion that abrogation of PTEN may be a common mechanism involved in resistance to 
targeted therapies across multiple cancer types.  Indeed, ErbB2-overexpressing breast tumors with 
reduced or absent PTEN are relatively resistant to trastuzumab-containing chemotherapy regimens 
(18).  Abrogated PTEN has also been associated with resistance to the EGFR inhibitor, gefitinib, in 
endometrial cancer cell lines (19) and resistance to imatinib in acute lymphoblastic leukemia (20).   
Importantly, PD173074 induced cell death and cell cycle arrest in the AN3CA cell line, despite loss 
of PTEN in this cell line.  These data suggest that loss of PTEN may not predict resistance to FGFR 
inhibitors in endometrial cancer. Interestingly, PD173074 treatment induced cell cycle arrest but did 
not result in enhanced annexin V staining in MFE296 cells (data not shown).   
Though the mechanism of PD173074-induced cell cycle arrest and apoptosis remains to be 
fully elucidated, it is intriguing to speculate that these phenotypes may be dependent on inhibition 
of FGFR-mediated MAPK activation.  Consistent with this hypothesis, AN3CA cells are sensitive to 
MEK inhibition, with UO126 treatment resulting in annexin-positive staining similar to that 
observed with PD173074 (Supplemental Figure 2).  
In summary, we have shown that FGFR2 mutations are coincident with PTEN inactivation 
and mutually exclusive with KRAS mutations in primary endometrioid endometrial cancers. 
Blockade of FGFR2 signaling by shRNA knockdown or treatment with a pan-FGFR inhibitor, 
PD173074, resulted in cell death and cell cycle arrest of endometrial cancer cell lines expressing 
mutationally activated FGFR2. Together these data suggest inhibition of constitutively active 
mutant FGFR2 may be therapeutically beneficial for endometrial cancer patients despite the 
frequent inactivation of PTEN in this tumor type. 
 
Footnotes 
4http://www.sanger.ac.uk/genetics/CGP/cosmic 
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Figure Legends 
 
Figure 1. shRNA mediated knockdown of FGFR2 induces cell death in endometrial cancer 
cells with activated FGFR2.  
(A and B) Effect of FGFR2 shRNA on cell proliferation of endometrial cancer cells with activating 
mutations in FGFR2.  AN3CA (A) or MFE296 (B) cells were transduced with empty vector, 
nonsilencing shRNA, or two independent FGFR2 shRNA constructs and the effect on cell 
proliferation assessed using the SRB assay. Treatment with FGFR2 shRNA suppressed proliferation 
of both cell lines. Nonsilencing control shRNA had no effect on cell proliferation. (C). Effect of 
FGFR2 knockdown on activation of ERK1/2 and AKT.  24 hours following shRNA transduction, 
AN3CA cells were serum starved in 0.2% FBS for 18 hours.  Lysates were collected and analyzed 
by Western blot for FGFR2 expression and activation of ERK1/2 and AKT.  Knockdown of FGFR2 
resulted in reduced ERK1/2 phosphorylation, and had no effect on AKT phosphorylation. (D). Cell 
death following knockdown of FGFR2. Following siRNA transfection, AN3CA cells were analyzed 
for annexinV-FITC positive cells by flow cytometry. Knockdown of FGFR2 resulted in an increase 
in annexinV positive cells, indicative of apoptosis.  Inset. Protein lysates were analyzed by western 
blot analysis to confirm FGFR2 knockdown. This knockdown was achieved with siRNAs rather 
than the shRNA constructs as the latter also expressed GFP, which has an overlapping emission 
spectra with FITC. 
 
Figure 2. Endometrial cancer cells with activating FGFR2 mutations are sensitive to 
PD173074, a pan-FGFR inhibitor. 
(A) PD173074 dose response curves for six endometrial cancer cell lines. Cell viability was 
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measured with the SRB assay 72 hours following addition of PD173074 and data normalized to 
DMSO (vehicle control) for each cell line. AN3CA and MFE296 cells carry the N550K FGFR2 
mutation. HEC1A, Ishikawa, KLE, and RL952 are wildtype for FGFR2. PD173074 treatment had a 
profound negative effect on cell viability of cell lines expressing mutant FGFR2 compared to those 
expressing wildtype FGFR2. PD173074 IC50 values:  AN3CA = 61.8nM; MFE296 = 284.3nM; 
HEC1A > 3000nM; Ishikawa = 2920.7nM; KLE > 3000nM; RL952 > 3000nM.   
 (B) Annexin staining reveals cell death of AN3CA cells following treatment with PD173074.  
AN3CA cells were treated with 0.1% DMSO (vehicle control) or 1 µM PD173074. 48, 72, or 96 
hours later, cells were collected and analyzed for annexin positive cells by flow cytometry.  The dot 
plots show representative samples following 96 hours of PD173074 treatment.  PD173074 treated 
cells showed an increase in annexin-V staining compared to cells treated with DMSO alone, 
indicative of apoptosis. 
(C) PD173074 leads to G1 cell cycle arrest in AN3CA cells.  Cells were treated with 1µM 
PD173074 and cell cycle analysis performed by propidium iodide staining and flow cytometry 72 
hours following addition of PD173074. PD173074 treatment resulted in an accumulation of cells in 
G1 phase of the cell cycle. 
 
Figure 3. PD173074 treatment markedly inhibits ERK1/2 but not AKT phosphorylation in 
endometrial cancer cells with activated FGFR2. 
(A) Cells were starved in 0.2% FBS overnight and then treated with 1µM PD173074 in 0.2% FBS 
for the indicated times of 0 to 72 hours. Lysates were collected and evaluated by Western blot 
analysis for activation of ERK1/2 and AKT.  PD173074 treatment resulted in marked suppression of 
ERK1/2 activation and modest suppression of AKT phosphorylation in AN3CA and MFE296 cells.  
PD173074 had no effect on ERK1/2 or AKT activation in HEC1A cells. Due to the low level of 
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phosphorylated AKT (Threonine 308) in HEC1A cells (13), the image shown here is an 
overexposure relative to the other pAKT blots presented.  
(B) AN3CA cells were starved in 0.2% FBS overnight, pretreated with or without 1µM PD173074 
for one hour, and then stimulated with 1nM FGF7 and 10 µg/ml heparin for five minutes. 
Phosphorylation status of FGFR2 was assessed by immunoprecipitating with a FGFR2 specific 
antibody and immunoblotting with a phosphorylation specific FGFR antibody.  The blot was then 
stripped and reprobed for total FGFR2.  The arrow indicates the fully glycosylated, cell surface 
expressed, mature receptor.  The lower band represents partially glycosylated, immature 
intracellular receptor.  In cells not pre-treated with PD173074, phosphorylation of the mature 
receptor (upper band, solid arrow) is evident, with an increase in receptor phosphorylation upon 
FGF7 stimulation. Phosphorylation of the receptor is abrogated upon pre-treatment with PD173074.  
Total levels of receptor are similar in all treatments.  The phosphorylation status of FRS2α was 
detected using a phosphorylation specific FRS2α antibody.  The blot was then stripped and 
reprobed for total FRS2α.  PD173074 treatment blocked basal and FGF7-stimulated 
phosphorylation of FRS2α. Total FRS2α was detected in all treatment conditions.  The change in 
mobility of FRS2α is due to the phosphorylation status of the protein, with phosphorylated FRS2α 
migrating slower than unphosphorylated FRS2α (14).  
 
 




Supplemental Figure 1. PTEN expression in endometrial cancer cell lines. 
Endometrial cancer cell lysates were collected and evaluated by Western blot analysis for 
PTEN expression.   
 
Supplemental Figure 2.  AN3CA endometrial cancer cells are sensitive to the MEK 
inhibitor, UO126. Treatment of AN3CA cells for 72 hours with 25 μM UO126 induced 
annexin positive staining similar to that observed following 1 μM PD173074 treatment. 
 


Target Forward Primer Reverse Primer
KRAS: Exon 1 5'-GTGACATGTTCTAATATAGTCA-3' 5'-CAGCATAATTATCTTGTAATAAG-3'
PTEN: Exon 1 5'-GTTTTAAACCTCCCGTGCG-3' 5'-ATCCGTCTACTCCCACGTTC-3'
PTEN: Exon 2 5'-CTCCAGCTATAGTGGGGAAAAC-3' 5'-AAGTCCATTAGGTACGGTAAGCC-3'
PTEN: Exon 3 5'-AACCCATAGAAGGGGTATTTG-3' 5'-AACAATGCTCTTGGACTTCTTG-3'
PTEN: Exon 4 5'-AAAGATTCAGGCAATGTTTGTTAG-3' 5'-TGTATCTCACTCGATAATCTGGATG-3'
PTEN: Exon 5 5'-GGAATCCAGTGTTTCTTTTAAATACC-3' 5'-TTTCCAATAAATTCTCAGATCCAG-3'
PTEN: Exon 6 5'-AATGGCTACGACCCAGTTACC-3' 5'-CAAATGCTTCAGAAATATAGTCTCC-3'
PTEN: Exon 7 5'-TGCTTGAGATCAAGATTGCAG-3' 5'-TCACCAATGCCAGAGTAAGC-3'
PTEN: Exon 8 5'-CTCAGATTGCCTTATAATAGTCTTTG-3' 5'-GTCAAGCAAGTTCTTCATCAGC-3'
PTEN: Exon 9 5'-AGCTTGGCAACAGAGCAAG-3' 5'-GTGCAAAGGGGTAGGATGTG-3'
Supplemental Table 2.  KRAS and PTEN primer sequences
Case ID Stage Grade MSI Status
FGFR2 Nucleotide 
Mutation
a
FGFR2 Amino Acid 
Mutation
b
KRAS Nucleotide 
Mutation
c
KRAS Amino Acid 
Mutation
d
PTEN Nucleotide Mutation
e
PTEN Amino Acid M
AN3CA  A929G,T1650G p.[Lys310Arg(+)Asn550Lys] wt wt c.389delG p.Arg130fsX4
MFE296 c.T1650G p.Asn550Lys wt wt wt wt
HEC1A  wt wt c.G35A p.Gly12Asp wt wt
1574 IC II + c.C755G p.Ser252Trp wt wt c.[131-137del7(+)204C>G] p.[Gly44AlafsX7(+)
1484 IIIC III - c.C755G p.Ser252Trp wt wt c.[388C>G(+)T166G] p.[Arg130Gly(+)F
1316 IIIC I - c.C755G p.Ser252Trp wt wt c.334C>G p.Leu112Va
1482 IVA II + c.C755G p.Ser252Trp wt wt c.955-958DelACTT p.Thr319X
1359 IB II + c.C755G p.Ser252Trp wt wt wt wt
1792 IIIC I + c.C755G p.Ser252Trp wt wt wt wt
1492 IC I - c.[C755G(+)A1127G] p.[Ser252Trp(+)Tyr376Cys] wt wt c.388C>G p.Arg130Gly
1684 IB I + c.C1118G p.Ser373Cys wt wt c.388C>G p.Arg130Gly
1655 IIIC II + c.A1127G p.Tyr376Cys wt wt c.922-928del7 p.Arg308IlefsX
1094 IB I + c.T1147C p.Cys383Arg wt wt c.321-326del6 p.Leu108-Asp1
1361 IB I + c.T1175G p.Met392Arg wt wt c.955-958DelACTT p.Thr319X
1744 IIIC II + c.A1642G p.Ile548Val wt wt c.[60delA(+)G198T] p.[Phe21SerfsX2(+
1267 IIA II + c.T1650A p.Asn550Lys wt wt c.377C>A p.AlaA126As
1391 IIIC II + c.T1650A p.Asn550Lys wt wt c.C733T p.Q245X
1528 IVA II - c.T1650G p.Asn550Lys wt wt c.388C>G p.Arg130Gly
1717 IC II - c.A1978G p.Lys660Glu wt wt c.176C>A p.Ser59X
1272 IA I - c.Intron10 A>C+2 wt wt wt wt
1289 IC III + c.2290-91DelCT p.Thr762fsX3 c.G35A p.Gly12Asp wt wt
1393 IIIC II + wt wt c.G34T p.Gly12Cys c.9-10delCA p.Ile4HisfsX5
1609 IB III + wt wt c.G34T p.Gly12Cys del 1bp A 800 p.Lys267ArgfsX
1606 IB I - wt wt c.G35A p.Gly12Asp c.[209+5G>A(+)572delT] p.Val191GlyfsX
1284 IIA I + wt wt c.G35A p.Gly12Asp c.[388C>G(+)493G>A] p.[Arg130Gly(+)Gly
1856 IB II + wt wt c.G35A p.Gly12Asp wt wt
1411 IIIC II + wt wt c.G35C p.Gly12Ala c.[139A>G(+)493G>A] p.[R47G(+)Gly16
1966 IIIC II + wt wt c.G35C p.Gly12Ala c.[388C>T(+)441-444delGGCA]       p.[Arg130X(+)Ala148
1599 IIIC II + wt wt c.G35T p.Gly12Val c.[388C>G(+)511C>T] p.[Arg130Gly(+)Gln
1044 IIIA III + wt wt c.G35T p.Gly12Val c.389G>A p.Arg130Gln
1873 IA I + wt wt c.G35T p.Gly12Val c.867delA p.V290X
1287 IIIA I - wt wt c.G38A p.Gly13Asp c.[367C>T(+)376G>T] p.[H123Y(+)Ala12
1576 IC II + wt wt c.G38A p.Gly13Asp c.389G>A p.Arg130Gln
1664 IIIC I - wt wt c.G35A p.Gly12Asp c.46dupT p.Tyr16LeufsX
1656 IB I - wt wt c.G35T p.Gly12Val c.750-751dupTG p.Gly251ValfsX
1724 IB I - wt wt wt wt c.[388C>G(+)493G>A] p.[Arg130Gly(+)Gly
1669 IVB III + wt wt wt wt c.389G>T p.Arg130Leu
1648 IB I - wt wt wt wt c.39-65del27 p.Arg14-Asp22deli
1350 IIIC III - wt wt wt wt c.[209+1Del4GTAA(+)862-863delGA] p.Glu288LysfsX
1441 IIIC III - wt wt wt wt c.[367C>T(+)389G>A] p.[His123Tyr(+)Arg1
1557 IIIC II + wt wt wt wt c.[384G>T(+)428delG] p.[Lys128Asn(+)Gly14
1120 IIB II - wt wt wt wt c.[388C>G(+)389delG] p.[Arg130Gly(+)Arg13
1062 IC II + wt wt wt wt c.[388C>G(+)968delA] p.[Arg130Gly(+)Asn323
8 IB I - wt wt wt wt c.[395G>A(+)959T>G] p.[Gly132Asp(+)Le
1539 IIIC I + wt wt wt wt c.[407G>A(+)598-599delTT] p.[Cys136Tyr(+)F2
1221 IC I - wt wt wt wt c.[520T>G(+)1027-2A>G] p.Tyr174Asp
1875 IB I + wt wt wt wt c.[532delT(+)c.802-1G>A] p.Tyr178IlefsX
1504 IIIA I - wt wt wt wt c.[635-1G>A(+)955-958delACTT] p.Thr319X
1562 IVB II + wt wt wt wt c.[639-663del25insGGCAA(+)898delA] p.[Gln214AlafsX21(+)Ile3
1900 IB I + wt wt wt wt c.[697C>T(+)1027-1G>A ] p.Arg233X
1184 IIIC I + wt wt wt wt c.[713dupT(+)867dupA] p.Met239HisfsX3(+)Val2
1637 IIIA II + wt wt wt wt c.[950-954delTACTT(+)c.968dupA] p.[Val317AspfsX5(+)Asn
1226 IVB II - wt wt wt wt c.[A71G(+)388C>G] p.[Asp24Gly(+)Arg1
1763 IIB I - wt wt wt wt c.[A80G(+)355delG(+)T824C] p.[Y27C(+)Val119fsX14
1898 IB I + wt wt wt wt c.[G850T(+)G871T]      p.[E284X(+)E29
1236 IIIA III + wt wt wt wt c.209+1del2GT
1296 IVB III - wt wt wt wt c.209+5G>A
1126 IIIC III - wt wt wt wt c.227_228delAT p.Y276X
1730 IB II + wt wt wt wt c.254+5G>A
1463 IIIC I + wt wt wt wt c.254-1G>C
1896 IA I + wt wt wt wt c.362-363delCA Ala121AspfsX
1330 IIIA I + wt wt wt wt c.367C>T p.His123Tyr
1607 IA I - wt wt wt wt c.370T>A p.Cys124Ser
1424 IB II - wt wt wt wt c.371G>C p.Cys124Tyr
1251 IB II - wt wt wt wt c.388C>G p.Arg130Gly
1495 IIA I + wt wt wt wt c.388C>G p.Arg130Gly
1501 IIIA III - wt wt wt wt c.388C>G p.Arg130Gly
1205 IA I - wt wt wt wt c.388C>G(+)932DelA p.Arg130Gly(+)Asn31
1191 IIA I - wt wt wt wt c.389G>A p.Arg130Gln
1727 IC I + wt wt wt wt c.389G>A p.Arg130Gln
1990 IIIA II - wt wt wt wt c.389G>A p.Arg130Q
1611 IC I - wt wt wt wt c.389G>C p.Arg130P
1112 IC II + wt wt wt wt c.410-414del5 p.Ala137ValfsX
1897 IB II + wt wt wt wt c.48-49delTC p.y16*
1556 IVB I - wt wt wt wt c.520T>G p.Tyr174Asp
1078 IIIC II + wt wt wt wt c.534T>A p.Tyr178X
1628 IB I - wt wt wt wt c.593T>A p.Met198Lys
1673 IVB I - wt wt wt wt c.662delA p.Lys221Argfs
1352 IIIC III - wt wt wt wt c.697C>T p.Arg233X
1984 IVB III + wt wt wt wt c.741-742InsA p.Pro248HisfsX
2027 IIIA III + wt wt wt wt c.800DelA p.Lys267ArgfsX
1600 IB III - wt wt wt wt c.801+1G>T
1652 IIIC II + wt wt wt wt c.802-2A>T
1645 IC II + wt wt wt wt c.878DelG p.Gly293GlufsX
1570 IVB II - wt wt wt wt c.883-884delCT p.Leu295Metfs
1621 IB I - wt wt wt wt c.955-958DelACTT p.Thr319X
1685 IIIC II - wt wt wt wt c.955-958DelACTT p.Thr319X
1977 IIIA I - wt wt wt wt c.968dupA p.N323KfsX1
1193 IIB I - wt wt wt wt c.T48A(+)386G>A p.Tyr16X(+)Gly12
1796 IA I - wt wt wt wt c.T68G p.Leu23X
2 IIB III - wt wt wt wt wt wt
1052 IVB II - wt wt wt wt wt wt
1087 IC II + wt wt wt wt wt wt
1093 IB I - wt wt wt wt wt wt
1119 IIIC III - wt wt wt wt wt wt
1194 IIIC III - wt wt wt wt wt wt
1209 IB II + wt wt wt wt wt wt
1282 IB II - wt wt wt wt wt wt
1370 IC III - wt wt wt wt wt wt
1419 IIIC III - wt wt wt wt wt wt
1470 IB II - wt wt wt wt wt wt
1474 IIIC III - wt wt wt wt wt wt
1500 IIIA III - wt wt wt wt wt wt
1507 IIIA III - wt wt wt wt wt wt
1513 IC I - wt wt wt wt wt wt
1514 IB III - wt wt wt wt wt wt
1555 IB III - wt wt wt wt wt wt
1569 IIIA I + wt wt wt wt wt wt
1601 IB II - wt wt wt wt wt wt
1632 IB II + wt wt wt wt wt wt
1639 IB III - wt wt wt wt wt wt
1644 IB III - wt wt wt wt wt wt
1650 IA I + wt wt wt wt wt wt
1707 IIIC II + wt wt wt wt wt wt
1740 IB I - wt wt wt wt wt wt
1756 IA I - wt wt wt wt wt wt
1767 IA I - wt wt wt wt wt wt
1781 IA I - wt wt wt wt wt wt
1790 IB I - wt wt wt wt wt wt
a
Numbering relative to NM_022970.2. 
b
Numbering relative to NP_075259.2. 
c
Numbering relative to NM_033360.2. 
d
Numbering relative to NP_203524.1. 
e
Numbering relative to NM_000314.4. 
f
Numbering relative to NP_000305
